Andrew Zupnick has focused exclusively on oncology for over 20 years and serves as the Vice President, Catalyst Oncology. He leads Catalyst’s full-service oncology solution, supporting study optimization, delivery oversight, training and new initiatives across the commercial and operational teams to keep Catalyst at the forefront of industry trends and cutting-edge oncology therapies. Andrew is a Cell and Molecular Biologist with a PhD from Columbia University and a BS from MIT. Andrew began his professional career at Prologue Research, a niche oncology CRO, which was founded out of what became the James Cancer Center at The Ohio State University and acquired in 2010 by Novella Clinical. At Novella, Andrew led the growth of the organization’s oncology division into a market-leading oncology specialty CRO. After the acquisition of Novella by Quintiles, Andrew spent nearly seven years working within the standalone CRO, which was subsequently rebranded to IQVIA Biotech in 2019.